SkinHealth Systems Inc. (SKIN) · Nov 5, 2026 · Earnings
Beat — Adjusted EBITDA $13.4M vs $5–7M Q3 guide; sales $69.2M vs $65–70M guide
SkinHealth Systems earnings show a wide adjusted EBITDA beat and better margins, but revenue remains below last year as delivery-system demand weakens.
SkinHealth Systems is rebuilding its Hydrafacial-centered medical-aesthetics platform around recurring consumables, a large provider-installed base, and newer offerings such as SkinStylus and HydraScalp. The prior quarter already showed the strategy working better on margins than on demand, with management emphasizing cost discipline and portfolio expansion.
The quarter beat the company’s operating-profit benchmark, not its growth problem. Q3 revenue of $69.2 million landed inside the prior $65–70 million company guide, but adjusted EBITDA of $13.4 million was well above the $5–7 million target. There is no dependable analyst consensus in the available record, so the company’s own prior guidance is the cleanest benchmark. The EBITDA outperformance reflects cost control and margin improvement rather than a sales acceleration.
| Metric | Q3 2026 | Q3 2025 | Prior guide |
|---|---|---|---|
| Net sales (Financial Highlights) | $69.2M | $70.7M | $65–70M |
| Consumables net sales (Financial Highlights) | $50.4M (+1.2%) | $49.8M | |
| Delivery Systems net sales (Financial Highlights) | $18.8M (-9.6%) | $20.8M | |
| Adjusted EBITDA (Financial Highlights) | $13.4M (+50.6%) | $8.9M | $5–7M |
| Adjusted EBITDA margin (Financial Highlights) | 19.3% (+6.7 pts) | 12.6% | |
| Cash and restricted cash (Balance Sheet) | $112.4M | $232.7M at Dec. 31, 2025 |
Recurring consumables are stabilizing, but the equipment funnel is still contracting. Consumables returned to modest growth, up to $50.4 million from $49.8 million, while Delivery Systems revenue fell to $18.8 million from $20.8 million and systems placed declined to 798 from 875. That mix matters: consumables support the installed-base economics, but weaker new placements limit future expansion of that recurring revenue pool.
The margin recovery is real, but partly comes from lower spending and favorable cost comparisons. Gross margin rose to 68.2% from 64.6%, adjusted operating expenses fell to $36.3 million from $39.1 million, and the company moved from an $11.0 million quarterly net loss to a $0.9 million loss. That is meaningful execution progress, although the release attributes much of the improvement to lower personnel and professional-fee spending, prior-year trade-in costs, tariff recoveries, and lower inventory charges—not to strong top-line growth.
Debt retirement improves the near-term maturity profile but materially reduces liquidity. SkinHealth Systems repaid the remaining $103.2 million of its 2026 Notes as planned, eliminating that immediate maturity. The trade-off is clear: cash fell to approximately $112 million from $233 million at year-end, while $243 million of convertible senior notes remain outstanding. 〔0〕
Bottom line: This is a genuine operating beat driven by much better profitability than expected, but it does not yet rewrite the growth story. SkinHealth Systems is becoming leaner and more cash-generative while its core equipment demand remains under pressure and liquidity is thinner after debt repayment.
Q4 2026 results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!